Navigation Links
Riverside Partners Invests in BioAgilytix Labs
Date:6/4/2013

BOSTON and DURHAM, N.C., June 4, 2013 /PRNewswire/ -- Riverside Partners, a Boston-based private equity firm, is pleased to announce that it has completed an investment in BioAgilytix Labs  ("BioAgilytix"), a leading contract bioanalytical laboratory specializing in large molecule biologic drugs. Riverside Partners' investment was completed in partnership with the BioAgilytix Founders and management team.

Headquartered in Research Triangle Park, North Carolina, BioAgilytix provides outsourced laboratory services to customers within the pharmaceutical, biotechnology, and agriculture industries. By developing, optimizing and conducting bioanalytic testing, the Company offers its customers a high-quality outsourcing option, which supports drug discovery, pre-clinical and clinical development, and manufacturing.

"The BioAgilytix team is very excited work with Riverside Partners.  The Riverside team has a great understanding of how to scale a pharmaceutical services business, and the two organizations have a very strong cultural fit," said Jim Petrilla , Co-Founder and CEO of BioAgilytix.

"Co-Founders Jim Petrilla and Dr. Afshin Safavi have built a terrific business focused on supporting large molecule drug development, a very exciting area within the pharmaceutical and biotechnology industries.  Riverside Partners is looking forward to utilizing our deep healthcare experience to help accelerate the Company's growth," said Philip Borden , General Partner at Riverside Partners. 

About BioAgilytix Labs

BioAgilytix Labs is a specialized bioanalytical testing laboratory focused on large molecule bioanalysis for the pharmaceutical, biotechnology and agriculture industries. BioAgilytix Lab's mission is to provide outsourced analysis of biological samples that supports the work of companies seeking regulatory approval of their biopharmaceutical and agricultural products. For more information on the Company, please visit www.bioagilytix.com.        

About Riverside Partners 

Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Partners Fund V, L.P.  The fund focuses on growth-oriented companies primarily in the healthcare and technology industries.  Riverside Partners is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies.  Today, Riverside Partners manages $1 billion of equity capital and seeks to make investments in companies with revenues between $20 and $200 million and with $5-$25 million of EBITDA.  

For more information, please visit

www.riversidepartners.com

Copyright 2009, Riverside Partners, LLC.


'/>"/>
SOURCE Riverside Partners
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Fuse Science Partners With GNC To Open National Distribution Of EnerJel™
3. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
4. The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
5. ClearCanvas Partners With DPR to Offer CaseReader™, an Integrated Technology Structured Reporting Solution for Medical Imaging Professionals
6. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
7. Bayer Partnership Delivers Industry-First Dose Management Offering
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
10. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
11. UBM Canon, the Global MedTech Authority, Partners with the World Medical Device Organization, WMDO, to Provide Medical Device Companies with Industry-Related Online Training Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):